Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Importance of Screening for HCC in HBV: Patient and Physician Sharing Session #7

Source: Addressing Misunderstandings in Applying HBV Treatment Guidelines
In this episode in our series of sharing sessions between a physician and patient, Ming-Lung Yu, MD, PhD, and his patient, who is living with chronic hepatitis B, discuss the importance of screening for HCC even when HBeAg negative without overt ALT elevation.
Ming-Lung Yu, MD, PhD
Released: April 12, 2022

In episode 7 of a series of sharing sessions between a physician and patient, Ming-Lung Yu, MD, PhD, and his patient, who is living with chronic hepatitis B, discuss:

  • Role of family history in risk of hepatocellular carcinoma (HCC)
  • Surveillance for HCC
  • Steps to take when diagnosed with HCC
  • How to live a healthy life after HCC diagnosis and treatment

Information on this Educational Activity

Faculty

Ming-Lung Yu, MD, PhD

Chair Professor
Hepatobiliary Division
Department of Internal Medicine and Hepatitis Center
Kaohsiung Medical University
Visiting Staff
Hepatobiliary Division
Department of Internal Medicine
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan

Ming-Lung Yu, MD, PhD, has disclosed that he has received funds for research support from Abbott, Bristol-Myers Squibb, Gilead Sciences, and Merck; consulting fee sform AbbVie, Abbott, Ascletis, Bristol-Myers Squibb, Gilead Sciences, Merck, and Roche; and fees for non-CME/CE services from AbbVie, Abbott, Bristol-Myers Squibb, Gilead Sciences, Ipsen, and Merck.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from:
Gilead Sciences, Inc.

Related Content

Clinical Care Options (CCO) expert audio: Dr Carla Coffin discusses investigational HBV cure strategies

person default Carla Coffin, MD Released: June 30, 2022

Clinical Care Options (CCO) commentary from a patient who shares their experience of severe liver disease from HBV/HDV coinfection

person default Joaquín (Patient) Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 29, 2022 Expired: June 28, 2023

Patient perspectives and key action items to address in clinical settings to reduce HBV care barriers in the United States, from Clinical Care Options (CCO)

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Jennifer Wild, MS, BSN, RN, OCN Released: June 22, 2022

Clinical Care Options (CCO) commentary from Dr Carla Coffin on risks vs benefits of treating patients in the indeterminate category for HBV treatment

person default Carla Coffin, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 21, 2022 Expired: June 20, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings